Long-term safety of tezepelumab in Japanese Subjects with Inadequately Controlled Severe Asthma - NOZOMI
Study identifier:D5180C00019
ClinicalTrials.gov identifier:NCT04048343
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tezepelumab in Japanese Adults and Adolescents with Inadequately Controlled Severe Asthma (NOZOMI)
Medical condition
Severe Asthma
Phase
Phase 3
Healthy volunteers
No
Study drug
Biological: Experimental: Tezepelumab
Sex
All
Actual Enrollment
65
Study type
Interventional
Age
12 Years - 80 Years
Date
Study Start Date: 10 Jun 2019
Primary Completion Date: 18 Mar 2021
Study Completion Date: 18 Mar 2021
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verification:
Verified 01 Apr 2022 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
Amgen
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Tezepelumab Tezepelumab: Tezepelumab subcutaneous injection | Drug: Biological: Experimental: Tezepelumab Tezepelumab subcutaneous injection every 4 weeks Other Name: Tezepelumab |
Contacts
Investigators
Principal Investigator
Masaharu Shinkai
Tokyo Shinagawa Hospital Medical Corporation Association, Japan
